Literature DB >> 20814258

Behavior, brain, and genome in genomic disorders: finding the correspondences.

Elena L Grigorenko1, Alexander E Urban, Einar Mencl.   

Abstract

OBJECTIVE: Within the last decade or so, there has been an acceleration of research attempting to connect specific genetic lesions to the patterns of brain structure and activation. This article comments on observations that have been made based on these recent data and discusses their importance for the field of investigations into developmental disorders.
METHODS: In making these observations, the authors focus on one specific genomic lesion, the well-studied, yet still incompletely understood, 22q11.2 deletion syndrome.
RESULTS: The authors demonstrate the degree of variability in the phenotype that occurs at both the brain and behavioral levels of genomic disorders and describe how this variability is, on close inspection, represented at the genomic level.
CONCLUSION: The authors emphasize the importance of combining genetic/genomic analyses and neuroimaging for research and for future clinical diagnostic purposes and for the purposes of developing individualized, patient-tailored treatment and remediation approaches.

Entities:  

Mesh:

Year:  2010        PMID: 20814258      PMCID: PMC4124614          DOI: 10.1097/DBP.0b013e3181f5a0a1

Source DB:  PubMed          Journal:  J Dev Behav Pediatr        ISSN: 0196-206X            Impact factor:   2.225


  63 in total

1.  A neurogenomics approach to gene expression analysis in the developing brain.

Authors:  Patricia Jensen; Susan Magdaleno; Karen M Lehman; Dennis S Rice; Edward R Lavallie; Lisa Collins-Racie; J M McCoy; Tom Curran
Journal:  Brain Res Mol Brain Res       Date:  2004-12-20

2.  Developmental presentation of 22q11.2 deletion (DiGeorge/velocardiofacial syndrome).

Authors:  P P Wang; C Solot; E M Moss; M Gerdes; D M McDonald-McGinn; D A Driscoll; B S Emanuel; E H Zackai
Journal:  J Dev Behav Pediatr       Date:  1998-10       Impact factor: 2.225

3.  Catechol-O-methyl transferase and expression of schizophrenia in 73 adults with 22q11 deletion syndrome.

Authors:  Anne S Bassett; Oana Caluseriu; Rosanna Weksberg; Donald A Young; Eva W C Chow
Journal:  Biol Psychiatry       Date:  2007-01-09       Impact factor: 13.382

4.  High rates of schizophrenia in adults with velo-cardio-facial syndrome.

Authors:  K C Murphy; L A Jones; M J Owen
Journal:  Arch Gen Psychiatry       Date:  1999-10

Review 5.  Toward a developmental neurobiology of autism.

Authors:  Franck Polleux; Jean M Lauder
Journal:  Ment Retard Dev Disabil Res Rev       Date:  2004

6.  The Philadelphia story: the 22q11.2 deletion: report on 250 patients.

Authors:  D M McDonald-McGinn; R Kirschner; E Goldmuntz; K Sullivan; P Eicher; M Gerdes; E Moss; C Solot; P Wang; I Jacobs; S Handler; C Knightly; K Heher; M Wilson; J E Ming; K Grace; D Driscoll; P Pasquariello; P Randall; D Larossa; B S Emanuel; E H Zackai
Journal:  Genet Couns       Date:  1999

Review 7.  Velocardiofacial syndrome, DiGeorge syndrome: the chromosome 22q11.2 deletion syndromes.

Authors:  Lisa J Kobrynski; Kathleen E Sullivan
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

Review 8.  When half is not enough: gene expression and dosage in the 22q11 deletion syndrome.

Authors:  D W Meechan; T M Maynard; D Gopalakrishna; Y Wu; A S LaMantia
Journal:  Gene Expr       Date:  2007

Review 9.  Is COMT a susceptibility gene for schizophrenia?

Authors:  Hywel J Williams; Michael J Owen; Michael C O'Donovan
Journal:  Schizophr Bull       Date:  2007-04-04       Impact factor: 9.306

10.  Effects of a functional COMT polymorphism on brain anatomy and cognitive function in adults with velo-cardio-facial syndrome.

Authors:  T van Amelsvoort; J Zinkstok; M Figee; E Daly; R Morris; M J Owen; K C Murphy; L De Haan; D H Linszen; B Glaser; D G M Murphy
Journal:  Psychol Med       Date:  2007-05-10       Impact factor: 7.723

View more
  1 in total

1.  A case report of 22q11 deletion syndrome confirmed by array-CGH method.

Authors:  Maryam Sedghi; Narges Nouri; Hossein Abdali; Mehrdad Memarzadeh; Nayereh Nouri
Journal:  J Res Med Sci       Date:  2012-03       Impact factor: 1.852

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.